Colloidal Gold Conjugated, Goat anti-human IgG (H&L) - 50 OD
Polyester ribbons (3) impregnated with different OD values of conjugated Protein A
Polyester ribbon impregnated with conjugated Protein A - .25 OD per sq. cm.
Polyester ribbons (3) impregnated with different OD values of conjugated Protein G
Medicine Products:(Date:9/8/2008)... WASHINGTON, Sept. 8 /PRNewswire-USNewswire/ --...like soyfoods. A Montgomery Country,Maryland stud...uch as meat,counterparts. The trick -- replacing f...soyfoods., A plate waste study, funded by the Uni...ing macaroni & cheese, burgers, chicken nuggets, a...
(Date:9/8/2008)..., One million Swiss Francs (around $ 885 thousan...Half of the amount must be destined by the winners...- The names of the 2008 Balzan Prize winners were ...Calvesi (Italy), Universit di Roma "La Sapienza", ...), University of New York, for Moral Philosophy ,...
(Date:9/8/2008)... LegalView recently repor...sing proton pump inhibitor (PPI) drugs. The drugs ...he stomach as well as other stomach/intestinal iss...ase (GERD), dyspepsia, some forms of stomach infec... Denver, CO (PRWEB) September 8, 200...
(Date:9/7/2008)... A new analysis reveals that fewer than half of o...cancer receive the recommended screening schedule ...earing in the October 15, 2008 issue of CANCER , ...iety, indicates poor compliance to recommended mon...t survival. , Patients who undergo potentially c...
Breaking Medicine News(10 mins):Health News:Back to School With Soy 2Health News:Balzan Foundation announced 2008 prize winners 2Health News:Balzan Foundation announced 2008 prize winners 3Health News:LegalView Warns Proton Pump Inhibitor Patients of Potential Bone Fracture Risk Associated with Drug 2Health News:LegalView Warns Proton Pump Inhibitor Patients of Potential Bone Fracture Risk Associated with Drug 3Health News:LegalView Warns Proton Pump Inhibitor Patients of Potential Bone Fracture Risk Associated with Drug 4Health News:Many colorectal cancer survivors do not receive recommended follow-up care 2(Date:9/8/2008)...of clinical evidence demonstrating the efficacy an... of stress urinary inconti...swire/ -- A new study published in the,August issu...data of an,11-year follow up study on the safety a...) as a treatment for stress urinary incontinence (...
(Date:9/6/2008)...ng 95 Percent or Greater Concordance Compared to F...Breast -, - Company to Include Reporting for HER2 ... Reports by End of 2008 -, REDWOOD CITY, C...ealth,Inc. (Nasdaq: GHDX ) today announced resul...e reporting for HER2 gene expression, as measured ...
(Date:9/5/2008)... 5 /- CEL-SCI Corporation,(... rheumatoid arthritis data,at the Marcus Evans con...presented by Dr. Daniel Zimmerman, Senior Vice Pre..., indicate that CEL-SCI,s rheumatoid,arthritis vac...ssue damage,caused by rheumatoid arthritis in an a...
(Date:9/4/2008)...han designation for the treatment of Acute Myeloid...ON, N.J., Sept. 4 /- Celator Pharmace...Administration (FDA) has granted orphan,drug desig...me Injection,for the treatment of Acute Myeloid Le...conduct two randomized Phase 2,studies with CPX-35...
Breaking Medicine Technology:New Study Offers More Than a Decade of Evidence for Minimally-Invasive Surgery to Treat Female Incontinence 2New Study Offers More Than a Decade of Evidence for Minimally-Invasive Surgery to Treat Female Incontinence 3Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients 2Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients 3Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients 4Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients 5Data Suggest CEL-SCI's CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis 2Data Suggest CEL-SCI's CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis 3Data Suggest CEL-SCI's CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis 4Celator Pharmaceuticals Receives Orphan Drug Designation for Anticancer Agent CPX-351 2Long Term Followup in Phase 3 CLL Trial Shows Genasense 28R 29 is Associated with Significantly Increased Survival in All Responders 2221 1Long Term Followup in Phase 3 CLL Trial Shows Genasense 28R 29 is Associated with Significantly Increased Survival in All Responders 2221 2Long Term Followup in Phase 3 CLL Trial Shows Genasense 28R 29 is Associated with Significantly Increased Survival in All Responders 2221 3Long Term Followup in Phase 3 CLL Trial Shows Genasense 28R 29 is Associated with Significantly Increased Survival in All Responders 2221 4InterMune Announces Start of 14 Day Triple Combination Study of ITMN 191 in Patients With Chronic Hepatitis C 2219 1InterMune Announces Start of 14 Day Triple Combination Study of ITMN 191 in Patients With Chronic Hepatitis C 2219 2InterMune Announces Start of 14 Day Triple Combination Study of ITMN 191 in Patients With Chronic Hepatitis C 2219 3InterMune Announces Start of 14 Day Triple Combination Study of ITMN 191 in Patients With Chronic Hepatitis C 2219 4Wyeth Receives FDA Fast Track Designation for its 13 valent Pneumococcal Conjugate Vaccine for Infants and Toddlers 2217 1Wyeth Receives FDA Fast Track Designation for its 13 valent Pneumococcal Conjugate Vaccine for Infants and Toddlers 2217 2Wyeth Receives FDA Fast Track Designation for its 13 valent Pneumococcal Conjugate Vaccine for Infants and Toddlers 2217 3Wyeth Receives FDA Fast Track Designation for its 13 valent Pneumococcal Conjugate Vaccine for Infants and Toddlers 2217 4Type of Tomato Product Determines Power Against Prostate Cancer 20497 1Type of Tomato Product Determines Power Against Prostate Cancer 20497 2Type of Tomato Product Determines Power Against Prostate Cancer 20497 3...ENVER--(BUSINESS WIRE)--Apr 23, 2007 - Ceragenix P...ical company focused on,infectious disease and der...earch paper on two of the Company,s antimicrobial,... the April issue,of the Journal of Antimicrobial A...ournal of the American Society of,Microbiology, de...
...indings Illustrate Role of Innovative New Treatmen...sease, BASEL, Switzerland, April 23, 2007 /PRNewsw...monthly MIRCERA, a continuous,erythropoietin recep... one of the fastest growing groups of patients wit... who are on dialysis. In,this analysis, MIRCERA tr...
Other Medicine Technology:Ceragenix Announces New Publication of Scientific Research on,Ceragenin Technology 2Ceragenix Announces New Publication of Scientific Research on,Ceragenin Technology 3Ceragenix Announces New Publication of Scientific Research on,Ceragenin Technology 4Mircera Effective in Stabilising Haemoglobin Levels in Elderly,Patients With Kidney Disease on Dialysis 2Mircera Effective in Stabilising Haemoglobin Levels in Elderly,Patients With Kidney Disease on Dialysis 3Mircera Effective in Stabilising Haemoglobin Levels in Elderly,Patients With Kidney Disease on Dialysis 4Mircera Effective in Stabilising Haemoglobin Levels in Elderly,Patients With Kidney Disease on Dialysis 5